Core Viewpoint - The establishment of regional technology transfer centers in the Guangdong-Hong Kong-Macao Greater Bay Area aims to enhance the conversion of scientific research achievements from universities into industrial applications, particularly in the fields of biomedicine, intelligent transportation, and high-end scientific instruments. Group 1: Intelligent Transportation Sub-center - The Intelligent Transportation Sub-center has been approved and is located in Guangzhou University Town, focusing on integrating education, technology, and talent development [5] - The center aims to leverage Guangzhou's trillion-level new energy vehicle industry cluster and leading low-altitude economy to accelerate the transformation of research achievements into productive forces [5][6] - Currently, the center has engaged with 40 universities, collected 364 projects, and selected 65 quality projects, with 17 projects from various universities already established [6][7] Group 2: High-end Scientific Instruments Sub-center - The High-end Scientific Instruments Sub-center aims to address the low conversion rate of scientific achievements in universities and reduce reliance on imported high-end scientific instruments [8] - The center is building nine common technology platforms and three shared platforms to facilitate resource sharing and inject new momentum into the industry [8][9] - A phased funding model is being implemented, providing up to 1 million yuan for concept validation and up to 10 million yuan for industrial transformation for successful projects [8][9] Group 3: Biomedicine Sub-center - The Biomedicine Sub-center was established in August and is located on the International Biological Island in Guangzhou, which hosts over 530 biomedicine innovation companies [10] - The center focuses on cutting-edge areas such as "cell gene" and "AI + pharmaceuticals," aiming to solve the challenges of converting biomedicine research into practical applications [10] - Currently, 159 projects have been preliminarily selected for entry into the center, focusing on "cell gene therapy" and "AI pharmaceuticals" [10]